Company ProfilePremium

Asahi Songwon Colors Limited

Company Profile Analysis

Tickers: ASAHISONG.NS, 532853.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Asahi Songwon Colors Limited - Company showcase

Year Founded & Workforce

1990

Asahi Songwon Colors Limited logo

Asahi Songwon Colors Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Asahi Songwon Colors Limited Overview

Asahi Songwon Colors is a promoter-controlled Gujarat chemicals micro-cap (67.00% promoter holding, no pledge). It began as a single-product, single-site producer of copper phthalocyanine (CPC) blue pigments for the printing-ink industry. It is now a three-vertical group:

Phthalocyanine blue pigments: (Padra): backward-integrated into CPC blue crude.

Azo pigments: (Dahej): made through Asahi Tennants Color, a 51%-owned joint venture with Tennants Textile Colours (UK).

Active pharmaceutical ingredients (APIs): (Odhav and Chhatral): made through wholly owned Atlas Life Sciences, led by Pregabalin.

The core blue business supplies multinational ink and coatings majors, including DIC, Sun Chemical, Clariant and BASF (per CARE Ratings). It runs at 80–85% utilisation and generates the group's cash. The two newer engines turned EBITDA-positive in FY26 after a debt-funded investment cycle that took borrowings to a peak of about ₹220 crore.

Management's stated agenda, "Calibrated for growth", targets ₹1,000 crore revenue and about ₹100 crore EBITDA over the coming years, funded largely from internal accruals. Q1 FY27 delivered record quarterly revenue (₹188.91 crore) and a 16.8% operating margin.


What the company does

Asahi Songwon manufactures organic colour pigments and pharmaceutical active ingredients and sells them business-to-business. Its products are inputs, not consumer brands. The pigments business converts petrochemical-derived intermediates into high-purity colorants. The key inputs are phthalic anhydride, urea and copper salts for CPC blue crude (inferred from standard CPC chemistry). CARE Ratings separately notes a supply arrangement for phthalic anhydride (CARE, Nov 2020).

The colorants are sold to manufacturers of printing inks, packaging inks, paints and coatings, plastics masterbatches, textiles, rubber and paper. The API business manufactures bulk drug substances, including anticonvulsant, antipsychotic and antidiabetic molecules, and sells them to formulators. It is backward-integrated into key intermediates.

Company's own description (paraphrased from AR FY26)

The company describes itself as one of the established global manufacturers of phthalocyanine blue pigments. It says it is building two further businesses, in Azo pigments and in APIs. It frames the blue pigments business as its foundation, dependable in cash generation and market standing. It says the Azo and pharmaceutical businesses crossed an important threshold in FY26, each turning profitable at the operating level and reaching cash break-even.

The FY26 report is themed "Calibrated for growth". Its core message is that the heavy capital spending is complete. Management will now raise utilisation at newer plants, hold realisations and efficiency in blue pigments, convert backward integration into a durable cost advantage, and direct cash towards a lighter balance sheet.

Business model and revenue model

DimensionCharacterisation
Revenue model~100% product sales (manufactured goods). No subscription, licensing or service revenue is disclosed. Minor other income: ₹6.70 crore in FY26 (AR FY26).
Sales channelDirect B2B sales to multinational and domestic manufacturers. Long-term supply agreements with key customers have run for up to 18 years (AR FY26).
Customer count101 customers (FY26), up from 19 in 2014 (AR FY26)
Customer stickiness80% of business from repeat customers. Longest single-customer collaboration is 21 years. The company says it has lost no customers and had zero product returns in three decades (AR FY26 — company claims).
Export intensityExports were 69% of standalone revenue in FY26, up from 64% in FY25 (AR FY26)
End-market diversificationRevenue from the ink industry has fallen from more than 90% to about 45% of the total, as the company diversified into paints, plastics, textiles and pharma (AR FY26)
PricingLargely contract and negotiated pricing with raw-material pass-through. FY26 second-half realisation gains were partly supported by passing through higher raw-material prices (AR FY26 MD&A).

Value-chain position

Blue pigments: The company is integrated from CPC blue crude (the key intermediate) to finished Beta Blue and Alpha Blue pigments. One tonne of finished Beta or Alpha blue needs about one tonne of crude, so in-house crude is the main cost and supply-security lever (AR FY26). Screener's company profile describes Asahi as the world's largest producer of CPC Blue crude. The AR uses the more cautious phrase "one of the larger producers of the crude globally". This difference is noted.

Azo pigments: These are mid-stream coupling-chemistry pigments (reds, yellows, oranges). Inputs are sourced within the Dahej chemical cluster (AR FY26).

APIs: Atlas is integrated into intermediates (for example, R-CMH, the key Pregabalin intermediate) at Chhatral. Finished API is made at the WHO-GMP-certified Odhav plant (AR FY26; acquisition press release, Apr 2022).

Customer types and end-markets

End-marketProducts usedNotes
Printing and packaging inksBeta Blue (PB 15:3 type), Alpha Blue, Azo yellows and redsHistorically more than 90% of revenue; now about 45% (AR FY26)
Paints and coatings (architectural, automotive, industrial)Beta and Alpha Blue, AzoAR cites rising use of CPC blue in premium automotive and architectural coatings
Plastics and masterbatchBlue and Azo—
TextilesBlue and Azo—
Rubber and paperBlue—
Pharmaceuticals (generic formulators)Pregabalin, Amisulpride, Levosulpiride, Gliclazide, Etoricoxib, PhenylephrineThrough Atlas Life Sciences

Independent characterisation

Asahi Songwon is best understood as a cash-generative, high-utilisation niche commodity-specialty pigment franchise attached to two sub-scale growth options.

The franchise is phthalocyanine blue. Its economics are cyclical but structurally advantaged by India's shift to being the dominant global source of the category (over 70% of global phthalocyanine demand, per the AR). The two options are Azo pigments and APIs. Each has consumed capital and management attention since 2019-22 and contributed losses through FY23-FY25.

The equity story therefore hinges on three things:

  • Whether blue-pigment margins can be held in the mid-teens through the cycle.

  • Whether the subsidiaries can move from break-even to the 13–16% operating margins management targets.

  • Whether free cash flow keeps deleveraging the balance sheet.

The Q1 FY27 print (16.83% operating margin, net profit ₹19.2 crore) is the first strong evidence for that thesis. A single quarter is not yet proof that it is durable.

Strategy

Stated strategy themes (AR FY26, paraphrased)

  1. "Calibrated for growth". The building phase is over. The task is to raise returns on installed capacity, business by business, and convert them into growth and a stronger balance sheet.

  2. Phthalocyanine: "Protect and sustain". Utilisation is already high, so the priority is durable margins rather than new capacity. The levers are disciplined pricing, de-bottlenecking, internal efficiency and value-added customer work. Management sees peak standalone EBITDA potential of about ₹50–55 crore. The Q4 FY26 call indicated this was achievable by FY27.

  3. Azo: "Raise utilisation, then expand". Lift utilisation towards the mid-80s, then spend ₹10–15 crore from internal accruals to add about 50% capacity. Win US and European export customers. Target a low-teens operating margin.

  4. API: "Fill the plant, certify, add products". Raise finished-API utilisation at Chhatral from about one-third of potential. Obtain CEP certification by end FY27. Broaden the molecule slate (ten in development). Target a 15–16% operating margin over time.

  5. Balance sheet. Keep cutting debt from the ~₹220 crore peak. Fund only small, high-return projects. Avoid large capital commitments.

Internal inconsistency on Azo utilisation. The Azo section of AR FY26 describes utilisation as "rising towards the mid-eighties". The growth-strategy page targets lifting it "from about 65%". The Q4 FY26 call (per arthneeti summary) guided from about 65% to 75–85% over three to four quarters. The 65% figure appears to be the current base.

Medium-term targets and guidance

TargetValueTimeframeSource
Group revenue ambition₹1,000 crore"Over the coming years" (unspecified)AR FY26
Consolidated EBITDA potentialAbout ₹100 croreUnspecifiedAR FY26
Standalone (blue) EBITDA₹50–55 crore peak potentialFY27 per Q4 FY26 callAR FY26; concall summary
Subsidiaries' peak revenue (Azo + API)₹250–280 crore, without further major capitalUnspecifiedAR FY26
Azo operating marginLow teensAs volumes buildAR FY26
API operating margin15–16%Over timeAR FY26
Azo utilisation~65% to 75–85%Next 3–4 quarters (from mid-2026)Q4 FY26 concall summary
Azo expansion capex₹10–15 crore, about +50% capacityTriggered at ~85% utilisationAR FY26
API CEP certificationGrantedBy end FY27 (31 Mar 2027)AR FY26
FundingLargely internal accruals; no major capex plannedOngoingAR FY26

Initiatives in the last 24 months

InitiativeStatus / detail
Blue de-bottlenecking and efficiency programmeOngoing. Management indicated in Jan 2025 that expected output gains would arrive in Q1 FY26 rather than Q4 FY25 (Q3 FY25 press release).
Azo debottlenecking and process optimisationUndertaken in FY25 (FY25 Directors' Report)
Chhatral backward integration (API intermediates)Commercial since 2023; 60–70% utilised
CEP filing for PregabalinIn progress; expected by end FY27
Leadership successionArjun Jaykrishna appointed CEO (May 2026)
Finance-function strengtheningNew CFO (Jul 2026)
SustainabilityAbout 80% process water recycled; effluent treatment plants at all sites; ISO 14001:2015 environmental management certification (per letterhead)
Borrowing authorityA postal ballot in May–June 2026 sought shareholder approvals. Media reports (scanx headline) reference CEO appointment and ₹150 crore loan approval.
Extraordinary General MeetingAn EGM notice appears in exchange announcements around Aug 2026 (5paisa feed).

Products & Services

Phthalocyanine pigments (parent company, Padra)

ProductDescription and key characteristicsTarget customers / applicationsLaunch / capacity historyPricing model
CPC Blue Crude (copper phthalocyanine crude)Key intermediate for all phthalocyanine blue pigments. Made in-house, which secures cost and supply. Also sold externally.Captive use plus pigment convertersTechnical collaboration with Clariant in 2003; capacity enhanced in 2008 and 2016B2B, negotiated
Beta Blue (Pigment Blue 15:3 family)Beta-crystal-form CPC blue, the industry workhorse cyan for process printing. Valued for colour strength, durability and semi-transparency. Third-party coverage (bottomstreet) identifies PB 15:3 as a primary product.Printing and packaging ink majors; also coatings and plasticsAdded in 2008; capacity expanded in 2010Contract or supply agreements with multinational ink makers
Alpha Blue (Pigment Blue 15:0 / 15:1 / 15:2 family)Alpha-crystal-form CPC blue with a redder shade. Used in coatings, plastics and textiles. Specific CI grades not disclosed.Paints, plastics, textilesAdded in 2016 as forward integrationB2B
Green pigments (historical)Phthalocyanine greenInks and coatingsBegan in 1993; segment demerged in 2014— (no longer offered)

Installed capacity for blue pigments (tonnes per annum) is not stated in the sources reviewed. Utilisation is 80–85% (AR FY26).

Azo pigments (Asahi Tennants Color Pvt. Ltd., Dahej)

ProductDescriptionTarget customersCapacity / status
Azo red pigmentsCoupling-chemistry organic reds. Specific CI numbers not disclosed.Inks, paints, plastics, textiles; mainly domestic, with export approvals in progress for the US and EuropePart of 2,400 TPA red-and-yellow capacity
Azo yellow pigmentsOrganic yellowsSameSame
Azo orange pigmentsReferenced in AR FY26 shade rangeSame—

Status: utilisation is rising towards the mid-80s per AR FY26. A brownfield expansion of ₹10–15 crore is planned once utilisation reaches about 85%. It would lift capacity by about 50%, because civil and structural work is already in place (AR FY26).

Active pharmaceutical ingredients (Atlas Life Sciences)

MoleculeTherapeutic classStatusNotes
PregabalinAnticonvulsant / neuropathic painFlagship; majority of API volumesCompany says it is the market leader in Pregabalin. Prices fell 40–45% after the acquisition and recovered about 15% from the low in FY26. A CEP-grade (EU regulatory) Pregabalin is expected after certification, targeted by end FY27.
R-Compound (R-CMH, Pregabalin intermediate)Key intermediateIn production at ChhatralGives backward integration and cost control
AmisulprideAntipsychoticCommercial—
LevosulpirideAntipsychotic / prokineticCommercial—
GliclazideAntidiabetic (sulfonylurea)Commercial—
EtoricoxibNSAID (COX-2 inhibitor)Commercial; described as recent—
PhenylephrineDecongestant / vasopressorListed in AR FY26 product panel—
PipelineTen products under development, including six new molecules and intermediates for existing productsR&DRun by a separate R&D centre (team of 11) plus Odhav labs

Pricing model: B2B sales of bulk API to formulators (domestic and export). Molecule-level pricing is not disclosed.

Financial Narrative

Basis:

  • Revenue, EBITDA, PAT, EPS and net worth are from AR FY26 KPIs (consolidated, ₹ crore).

  • Gross profit, operating income and interest expense are from a third-party data aggregator (stockanalysis.com, consolidated, INR million converted to ₹ crore). Its revenue figures reconcile exactly to the AR.

  • PBT is before exceptional items.

Note on PAT versus EPS. AR "PAT" is total group profit, including the non-controlling interest in the 51% Azo JV. EPS reflects profit attributable to owners. Because the JV made losses, owners' profit exceeds total PAT. For example, FY25 EPS of ₹16.76 implies owners' profit of about ₹19.75 crore, versus AR PAT of ₹16.86 crore.

Income statement (₹ crore unless stated)

Notes:

Diluted EPS: equals basic EPS. There are no convertibles, warrants or ESOPs outstanding (shareholding pattern declarations, 31 Mar 2026).

FY24 PAT: of ₹15.64 crore is after an exceptional gain from monetising non-core land (₹47 crore realised in 9M FY24, per CARE). The core business was loss-making before exceptional items (PBT -₹7.70 crore).

FY26 dividend: of ₹1.50 was recommended by the board on 29 Jul 2026, subject to AGM approval on 30 Sep 2026.

Margins and growth (%)

Revenue CAGR FY22→FY26 (derived): 6.9% per year: FY22 growth of 45.0% is from the aggregator and reflects the FY21 base.

Cash flow

Aggregator growth-rate data (roic.ai) shows free cash flow declined 27% in the latest year. That is directionally consistent with lower FY26 operating cash flow.

Quarterly trajectory (₹ crore)

Q1 FY25 and Q3 FY25 are derived from disclosed sequential growth rates (Q2 FY25 press release: +5.46% QoQ; Q4 FY25 press release: +14.23% QoQ). They sum to the FY25 total of ₹562.36 crore.

Data-quality flag. One outlet (scanx.trade) headlined Q1 FY27 profit as "₹192 crore". This is a unit error. The filing reports ₹1,923.20 lakh, which is ₹19.23 crore.

Commentary on trends, inflections and drivers

FY22 to FY23: the down-cycle and the acquisition. Revenue grew 22.8% in FY23 to ₹504.55 crore, helped by the first-time consolidation of Atlas (acquired April 2022). EBITDA, however, collapsed from ₹37.56 crore to ₹11.14 crore (margin 9.0% to 2.2%), and the group posted a ₹18.47 crore loss. CARE attributed the deterioration to three causes:

  • An adverse industry environment in the standalone pigment business, as customers destocked after the post-COVID surge.

  • High losses at the Azo JV, where plant stabilisation was delayed.

  • Higher interest from acquisition debt. Interest expense rose from ₹4.09 crore to ₹13.17 crore.

EBITDA interest cover fell below 1x in FY23. This was the low point of the company's recent history.

FY24: trough revenue, an exceptional rescue. Revenue fell 15.5% to ₹426.24 crore as destocking continued (CARE: blue utilisation of only about 60% in FY24; Azo about 54%). PBT before exceptional items was still negative at -₹7.70 crore. Reported PAT of ₹15.64 crore was produced by the ₹47 crore monetisation of non-core land, which CARE noted was used to shore up liquidity. Credit ratings fell further to A-.

FY25: cyclical recovery. Revenue rose 31.9% to ₹562.36 crore and EBITDA nearly tripled to ₹60.22 crore (10.6% margin). This reflected restocking, industry consolidation and blue utilisation above 85% (CARE, Jan 2025). Net profit attributable to owners was broadly flat because of finance costs and subsidiary losses.

FY26: lower revenue, better quality. Revenue fell 4.8% to ₹535.48 crore on soft global demand and tariff disruption. EBITDA margin held at 10.4%, finance cost fell 25.65%, and both new verticals reached EBITDA break-even. Operating cash flow of ₹43.24 crore funded ₹38.00 crore of financing outflows (debt reduction plus dividend). The year had a weak first half (Q1 FY26 net profit about ₹3 crore) and a strong fourth quarter (EBITDA ₹23.02 crore at 15.6%).

Q1 FY27: the inflection. Record revenue of ₹188.91 crore (+26% YoY, +31% QoQ) came with an operating margin of 16.83%, the highest in at least seven quarters. The drivers were blue-pigment volume and realisation gains, plus API price recovery (API segment result margin 14.0%).

What to watch. Azo revenue fell to ₹17.02 crore (versus a FY26 quarterly average of about ₹19.7 crore) as raw-material spikes led customers to defer purchases (MD commentary, Aug 2026). Durability across Q2 to Q4 FY27 is the key question.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipBusinessPlant(s)

Asahi Songwon Colors Limited

Parent (listed)

Phthalocyanine pigments: CPC blue crude, Beta Blue, Alpha Blue

Padra (Vadodara)

Asahi Tennants Color Private Limited

Subsidiary (51% JV with Tennants Textile Colours, UK, per CARE)

Azo pigments (red, yellow, orange)

Dahej (Bharuch)

Atlas Life Sciences Private Limited

Wholly owned subsidiary (100% since 26 Mar 2024)

APIs and intermediates

Odhav (Ahmedabad); Chhatral (Gandhinagar)

Atlas Life Sciences (India) Private Limited

Wholly owned subsidiary

Not separately described

—

Plutoeco Enviro Association

Associate

Not described; the name suggests a shared environmental / effluent association

—

Revenue by Segment

Segment (INR Cr)FY2024FY2025FY2026

Phthalocyanine pigments (standalone proxy; FY26 derived)

276.58390.22343.60

Azo + API subsidiaries combined (derived)

149.66172.14191.88

Consolidated revenue from operations

426.24562.36535.48

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

FY26 Vertical Detail Details

FY26 vertical detailRevenue (INR Cr)% of consolidatedProfit / (loss) before tax (INR Cr)Operating statusSource

Phthalocyanine (derived)

~343.60

~64.2%

~31.3 (derived: consolidated PBT 25.56 plus subsidiary losses)

Q4 FY26 EBITDA margin 15.6%

AR FY26

Azo pigments (Asahi Tennants Color)

78.9414.7%(2.42)

EBITDA-positive; cash break-even

AR FY26

API (Atlas Life Sciences)

112.9421.1%(3.34)

EBITDA-positive; cash break-even

AR FY26

Consolidated

535.48

100%

25.56 (before exceptional items)

EBITDA ₹56.53 crore (10.43%)

AR FY26

Segment growth (%)

Segment growth (%)FY2025FY2026

Phthalocyanine (standalone proxy)

41.1-11.9

Subsidiaries combined

15.011.5

Consolidated

31.9-4.8

Statutory Segment Details

Statutory segmentRevenue (INR Cr)Segment result (INR Cr)Result margin (%)Source

Pigments (Phthalocyanine + Azo)

155.1623.0814.9

Q1 FY27 integrated filing (NSE iXBRL)

API

34.544.8514.0

Same

Total

189.7027.9314.7

Same

Vertical revenue, Q1 FY27 (INR Cr)

Amount

Source

——

Phthalocyanine

138.14

Company press release via Indian Chemical News, 6 Aug 2026

——

Azo

17.02

Same

——

API

34.54

Same

——

Segment Overview

SegmentAssets (INR Cr)Liabilities (INR Cr)

Pigments

632.03227.46

API

172.30146.81

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

410.82504.55426.24562.36535.48

Gross profit (INR Cr, aggregator)

145.52119.20118.88185.80140.20

Operating income (INR Cr, aggregator)

20.00-9.582.0437.7931.10

EBITDA incl. other income (INR Cr)

37.5611.1421.0760.2256.53

Interest expense (INR Cr, aggregator)

4.0913.1711.7815.4912.24

PBT before exceptional items (INR Cr)

20.89-17.74-7.7024.9825.56

PAT, total group (INR Cr)

14.65-18.4715.6416.8617.78

EPS basic, owners (INR)

16.10-9.8317.0116.7615.92

Dividend per share for the year (INR)

0.500.500.501.501.50

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue growth YoY (%)

45.022.8-15.531.9-4.8

Gross margin (%, aggregator-derived)

35.423.627.933.026.2

Operating margin (%, aggregator-derived)

4.9-1.90.56.75.8

EBITDA margin (%, AR)

9.02.24.910.610.4

Net (PAT) margin (%, AR)

3.6-3.73.73.03.3

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Net worth / total equity (INR Cr)

284.43260.05265.95282.50297.88

Balance-sheet item (INR Cr)

FY2025

FY2026

Source / note

——

Total assets

—603.01

AR FY26 MD&A

——

Non-current assets

—303.51

AR FY26

——

Current assets

—299.50

AR FY26

——

Current liabilities

—239.98

AR FY26

——

Working capital (current assets less current liabilities)

—59.52

Derived

——

Non-current liabilities

80.8965.16

AR FY26

——

Gross debt

~163.9 (derived from debt/equity 0.58 × net worth)

~140.0 (derived from debt/equity 0.47)

AR FY26 ratio table

——

Net debt

—140.78

AR FY26 highlights

——

Cash and equivalents

—

Minimal (gross debt is close to net debt)

Derived

——

Peak borrowings during investment cycle

~220

—

AR FY26

——

“—” = not publicly disclosed.

Cash-flow item (INR Cr)

Cash-flow item (INR Cr)FY2025FY2026Source

Operating cash flow

57.9243.24

AR FY26

Net cash used in investing (capex proxy)

—6.78

AR FY26

Free cash flow (OCF less investing)

—36.46

Derived

Net cash used in financing

—38.00

AR FY26

Dividends paid (cash)

~5.9 (FY24 ₹0.50 × 1.1787 crore shares, paid Sep 2024; derived)

~17.7 (FY25 ₹1.50 × 1.1787 crore shares, paid Sep 2025; derived)

Derived from DPS

“—” = not publicly disclosed.

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE on closing equity (%, derived from AR PAT)

5.2-7.15.96.06.0

EBITDA interest coverage (x, derived)

9.20.81.83.94.6

Ratio

FY2025

FY2026

Source

——

Return on net worth (%)

66

AR FY26

——

ROA (PAT / total assets, %)

—2.9

Derived

——

ROIC (NOPAT / [equity + gross debt], %)

—

~6.0

Derived: EBIT ₹37.80 crore, ~30% tax, invested capital ~₹438 crore

——

Current ratio (x)

1.211.25

AR FY26

——

Debt / equity (x)

0.580.47

AR FY26

——

Net debt / EBITDA (x)

~2.7 (gross basis, derived)

2.49

Derived

——

Operating (PBIT) margin (%)

77

AR FY26

——

Net profit margin (%)

33

AR FY26

——

Debtors turnover (x)

4.143.73

AR FY26

——

Inventory turnover (x)

6.515.03

AR FY26

——

Asset turnover (x)

—0.89

Derived

——

Days sales outstanding (days)

8898

Derived (365 / debtors turnover)

——

Days inventory (days)

5673

Derived (365 / inventory turnover; AR basis not specified)

——

“—” = not publicly disclosed.

Income Statement

MetricQ1FY25Q2FY25Q3FY25Q4FY25Q4FY26Q1FY27

Consolidated revenue (INR Cr)

134.27141.61133.72152.75144.05188.91

Income Statement and Margin Analysis (%)

Q1 FY27 snapshotQ1 FY26Q4 FY26Q1 FY27Source

Revenue (INR Cr)

~149.9–151.3 (sources vary)

144.05188.91

Business Standard; Kotak; Q1 FY27 filing

EBITDA incl. other income (INR Cr)

~12.0 (derived)

23.0232.60

Indian Chemical News (company press release)

Operating margin excl. other income (%)

7.0413.5516.83

multibagg.ai, from filing

PBT (INR Cr)

~4.2

15.0725.34

Business Standard

Net profit attributable to owners (INR Cr)

3.1610.8719.23

Q1 FY27 filing via scanx / marketsmojo

Standalone net profit (INR Cr)

5.53—16.93

Q1 FY27 filing via scanx

Consolidated EPS (INR)

—9.2216.32

roic.ai; Kotak

“—” = not publicly disclosed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Region and Revenue by Region (%)

Region (INR Cr, standalone)FY2025FY2026

Export revenue (derived)

249.74237.08

Domestic revenue (derived)

140.48106.52

Export share (%)

6469

Region Overview

RegionMarkets disclosed

Americas

USA, Brazil

Europe

Spain, Belgium, UK, Italy, Germany

Asia-Pacific

China, Taiwan, Japan, Korea, Indonesia, Thailand, Singapore, Philippines, Malaysia, Vietnam

Middle East / Africa

UAE, South Africa

Share Price History

DatePrice (INR)ContextSource

18 Apr 2022

334.40

Atlas acquisition announcement

IIFL

21 Nov 2024

373.60

Recovery phase; P/E about 44x

INDmoney

15 Apr 2025

352.35—

Kotak

20 Oct 2025

277.10

One year before cut-off

TipRanks

5 Dec 2025

255.75

One-year return -39.4%

Equentis

22 Jan 2026

222.80

Six-month return -48.8%

Kotak Neo

2 Apr 2026

207.60

Near cycle low (52-week low ~₹179.64)

finanzen.ch

12 Jun 2026

257.89

Post-Q4 FY26

Torus

29 Jul 2026

354.60

Q1 FY27 results day

marketsmojo

7 Aug 2026

369.00

Market cap ₹435.9 crore; P/E 12.5x; P/B 1.6x

5paisa

11 Aug 2026

338.10

-4.99% on the day

IIFL

21 Sep 2026

364.00

Latest verified quote

Business Standard

Share Price & Returns

HorizonReturnBasis

One year

about +31%

Versus ₹277.10 on 20 Oct 2025 (derived)

Three years

about -3%

As of Dec 2025 (Equentis); not updated to the cut-off

Five years

about +11%

As of Dec 2025 (Equentis); not updated to the cut-off

Lifetime high / low

₹588.95 / ₹51.05

Anand Rathi

52-week range

High ~₹454–463, low ~₹179.64

Aggregators differ: ₹453.70, ₹454.75, ₹462.90

Valuation Snapshot

MultipleValueCalculation

Market cap

~₹429 crore

11,787,262 shares × ₹364

Enterprise value

~₹570 crore

Market cap plus FY26 net debt of ₹140.78 crore. EV is overstated if Q1 FY27 deleveraging is included, since the company reported strong deleveraging in Q1 FY27.

P/E (TTM)

~12.3x

TTM EPS of about ₹29.56 (FY26 ₹15.92 − Q1 FY26 ~₹2.68 + Q1 FY27 ₹16.32)

P/E (FY26)

~22.9x

FY26 EPS ₹15.92

EV / EBITDA (TTM)

~7.4x

TTM EBITDA of about ₹77.1 crore (FY26 ₹56.53 − Q1 FY26 ~₹12.0 + Q1 FY27 ₹32.60)

EV / Sales (TTM)

~1.0x

TTM revenue of about ₹574 crore

P/B

~1.4x

FY26 net worth of ₹297.88 crore (₹252.7 per share; includes non-controlling interest). 5paisa shows 1.6x.

Dividend yield

~0.4%

₹1.50 / ₹364

Dividend per share by payment year (INR)

Dividend per share by payment year (INR)2016201720182019202020212022202320242025

DPS paid (INR)

2.003.003.003.003.003.500.500.500.501.50

Analyst Ratings & Targets

DateLong-term ratingShort-term ratingActionDriver

25 Oct 2019

AA-; Stable

A1+ (also CP A1+)

Reaffirmed

Strong liquidity, comfortable leverage

18 Nov 2020

AA-; Stable

A1+

Reaffirmed

—

10 Nov 2021

AA-; Stable

A1+

Reaffirmed

—

26 Apr 2022

A+; Stable

A1+

Downgrade

Acquisition debt

14 Mar 2023

A; Stable

A1

Downgrade

Weak profitability; Azo JV losses

5 Apr 2024

A-; Stable

A2+

Downgrade

Continued weak coverage; land sale aided liquidity

17 Jan 2025

A; Positive

A1

Upgrade

Recovery; blue utilisation above 85%

2025 (later review)

A; Positive

A1

Reaffirmed

FY25 improvement

Facility Type Details

Facility typeAmount (INR Cr)

Long-term

17.49

Long-term / short-term

131.00

Short-term

19.00

Total

~167.5

Analyst Conclusions

Management guidance (summary)

  • Hold blue-pigment margins and reach standalone EBITDA of ₹50–55 crore (FY27 per the Q4 FY26 call).

  • Lift Azo utilisation from about 65% to 75–85% within three to four quarters, then spend ₹10–15 crore on expansion.

  • Obtain API CEP certification by March 2027 and raise finished-API utilisation from about 30%.

  • Long-term ambitions: ₹1,000 crore revenue and about ₹100 crore EBITDA.

  • No major capex; continued deleveraging; funding from internal accruals.

  • The MD said in August 2026 that he expects the strong momentum to continue through FY27.

Consensus: no institutional consensus exists (not publicly disclosed).

Bull case

  1. The blue franchise has re-based upward. Q1 FY27 phthalocyanine revenue of ₹138.14 crore is about 60% above the FY26 quarterly run-rate (derived from about ₹86 crore). Combined with 80–85% utilisation and weaker competitors exiting, this suggests the ₹50–55 crore standalone EBITDA guide is conservative.

  2. Operating leverage in the subsidiaries is large. Chhatral finished-API runs at about 30% utilisation, and management sees ₹250–280 crore of subsidiary revenue at peak without major capex, versus ₹191.88 crore in FY26. The API segment already earned a 14.0% result margin in Q1 FY27. CEP certification would add a higher-value regulated-market channel.

  3. Equity value should accrue from deleveraging. Net debt of ₹140.78 crore is falling. Free cash flow was about ₹36 crore in FY26, and management cited strong Q1 FY27 cash flows, at a modest EV/EBITDA of about 7.4x TTM. A CARE upgrade to A+ is plausible if FY27 tracks Q1.

Bear case

  1. One quarter is not a trend. The company's history shows violent cyclicality: EBITDA was ₹60.22 crore in FY25, ₹11.14 crore in FY23, and Q1 FY26 net profit was about ₹3 crore. Q1 FY27 benefited from restocking and raw-material pass-through that can reverse.

  2. Structural returns remain poor. ROE has been about 6% for three years, the Azo JV is still loss-making at the PBT level, and 49% of Azo upside belongs to the partner. Working-capital ratios deteriorated in FY26, with DSO lengthening to about 98 days.

  3. Governance and key-person risk. The company is family-run, with a 30-year-old CEO, a founder-Chairperson who is also an executive MD, two CFO exits in three years, and negligible institutional ownership (0.33%). Disclosure inconsistencies and a lack of institutional oversight increase the discount investors may demand.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableTimingWhat to watch
Q2 FY27 results~Late Oct / early Nov 2026 (expected 28 Oct, unconfirmed)Whether the operating margin holds at or above 14%; blue realisations; Azo recovery after the Q1 deferrals
Q3 FY27 / Q4 FY27 resultsFeb 2027 / May 2027Run-rate towards ₹50–55 crore standalone EBITDA
CEP certification (Pregabalin)By 31 Mar 2027 (guided)Grant or slippage
Azo utilisation reaching ~85%2,027Expansion capex trigger (₹10–15 crore)
Net debt trajectoryQuarterlyGross debt-to-equity below 0.4x; finance cost below ₹10 crore annualised
CARE rating reviewTypically annual (early 2027)Upgrade from A; Positive
US tariff and trade policyOngoingExport approvals for Azo; blue export demand
Pregabalin pricingOngoingSustainability of the ~15% recovery
New CFO's first full-year disclosuresFY27Quality of investor communication and working-capital discipline
EGM / postal ballot outcomes2,026Borrowing authorisations (₹150 crore reported) and their use

Analyst verdict

Asahi Songwon Colors is a genuinely advantaged niche business wrapped in an historically disappointing capital-allocation record. That record is now being repaired, but has not yet been fully proven.

The core phthalocyanine blue business is the real asset. It is backward-integrated, runs at 80–85% utilisation while a larger domestic rival runs at 40%, and serves global ink majors under multi-decade relationships. It sits in a category where India now supplies more than 70% of world demand.

The 2019–2024 diversification wasted much of that franchise's earning power. The Azo JV and the Atlas API acquisition came at the worst point of their cycles. Debt rose to about ₹220 crore, CARE downgraded the company three times, and the business needed a ₹47 crore land sale to stay comfortable on liquidity.

FY26 marked the turn, though not in revenue, which fell 4.8%. The turn was in quality. Both subsidiaries reached EBITDA break-even, finance cost fell by a quarter, and the balance sheet de-risked. Q1 FY27's record quarter (operating margin 16.83%, net profit ₹19.2 crore) is the first period in which all three engines contributed at once.

At about ₹364, the stock trades at roughly 12x trailing earnings and about 7x trailing EV/EBITDA. That is undemanding if Q1 FY27 represents the new base, and expensive (about 23x FY26 EPS) if it was a restocking spike.

Our assessment is that the evidence favours a structurally higher, but still cyclical, earnings base. Blue-pigment EBITDA of ₹50–55 crore looks achievable. API operating leverage and CEP certification provide credible upside, while Azo remains the weakest link.

The investment case is therefore positive but conditional. It needs confirmation over the next two quarters that margins hold at or above 14%, that receivables normalise, and that net debt keeps falling.

Governance concerns — founder-family concentration, CFO turnover, negligible institutional ownership and patchy disclosure — justify a persistent discount to larger Indian specialty-chemical peers. They also mean position sizing should reflect illiquidity.


SOURCES CONSULTED (primary sources first)

  • Asahi Songwon Colors Ltd, Annual Report 2025-26 ("Calibrated for growth"), filed with NSE and BSE on 5 Sep 2026 (NSE archives: AR_31632_ASAHISONG_2025_2026).

  • Asahi Songwon Colors Ltd, Q1 FY27 integrated financial results filing (iXBRL), 29 Jul 2026 (NSE archives).

  • Company press releases: Q2 FY25 (5 Nov 2024, BSE); Q3 FY25 (31 Jan 2025); Q4 FY25 (9 May 2025); Q4 FY24 (31 May 2024, BSE); Atlas Life Sciences acquisition (18 Apr 2022).

  • BSE disclosure ASCL/SEC/2023-24/61: acquisition of remaining 22% of Atlas Life Sciences (Mar 2024).

  • Shareholding patterns as of 31 Dec 2025 and 31 Mar 2026 (company website and exchange data via Emkay and Vogue).

  • CARE Ratings press releases: 25 Oct 2019; 18 Nov 2020; 10 Nov 2021; 26 Apr 2022; 14 Mar 2023; 5 Apr 2024; 17 Jan 2025.

  • FY25 Directors' Report (reproduced by IIFL / indiainfoline).

  • Indian Chemical News: Q4 FY26 (1 Jun 2026); Q1 FY27 (6 Aug 2026); Atlas acquisition (Apr 2022).

  • Business Standard: quarterly results page (Sep 2026); Atlas acquisition article (Apr 2022).

  • Exchange-filing aggregators: scanx.trade, boardstewardship.com, marketsmojo, multibagg.ai, sahi.com, bottomstreet, arthneeti (Q4 FY26 concall summary), DSIJ (25 Aug 2026), HDFC Sky, Kotak Neo / Kotak Securities, ICICIdirect, Screener.in.

  • Market-data aggregators: stockanalysis.com (Asahi and Sudarshan income statements), roic.ai, TipRanks, Equentis, Equitymaster, Upstox, 5paisa, Bajaj Finserv Markets, Anand Rathi, finanzen.ch, Torus, Choice India, Business Today, INDmoney.

  • Peer data: Sudarshan Chemical Q4 FY26 (Quartr; Arihant Capital result update; NSE investor presentation); Meghmani Organics Q4 FY26 press release (NSE), FilingReader, Arihant Capital, Screener.

  • Industry data as cited within AR FY26: IMF World Economic Outlook Update (Jan 2026); IBEF Chemicals (2025); Fortune Business Insights, Organic Pigments Market (2025); Grand View Research, India API Market (2025).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / key datesBackgroundAge

Mrs. Paru M. Jaykrishna

Founder, Chairperson and Managing Director

Founder; re-appointed as Chairperson & MD for 1 Aug 2026 – 31 Jul 2029 (subject to AGM)

Bachelor's degree in Law, Philosophy and Sanskrit. First elected woman president of an Indian industry association in seven decades. Former director of the Tourism Corporation of Gujarat and SIDBI.

—

Mr. Gokul M. Jaykrishna

Managing Director (CEO until 26 May 2026)

With the company since 1996; 17 years as MD and 8 years as CEO; re-appointed MD for 1 Aug 2026 – 31 Jul 2029

Finance major (economics minor), Lehigh University; previously at Krieger Associates (New Jersey). Director of Arvind Ltd and The Anup Engineering. President of the All India Pigment Manufacturers Association; associated with FICCI Gujarat.

—

Mr. Arjun G. Jaykrishna

CEO and Executive Director

CEO since May 2026; in charge of pigment marketing and plant operations

BS in Chemical Engineering (Sustainable Energy minor), Northwestern University; IB from UWCSEA Singapore. Previously at Deloitte (brownfield acquisitions) and DIC Japan. Son of Gokul Jaykrishna.

About 30 (scanx, citing the filing)

Mr. Mitesh N. Patel

Executive Director

With the company since 2006; re-appointment for 25 Oct 2026 – 24 Oct 2029 proposed

More than 20 years in chemicals; previously SVP, Commercial and Strategy Execution

—

Mr. Maulik P. Shah

Chief Financial Officer

Appointed 8 Jul 2026

More than 20 years' experience, including at AIA Engineering and Hitachi

—

Mr. Joseph Saji Varghese

Company Secretary and Compliance Officer

Current

——

Mr. Jagdish Sheth

Joint MD of Atlas Life Sciences at acquisition (2022)

———

“—” = not publicly disclosed.

Board of Directors

DirectorCategory (inferred where not labelled)Other affiliations

Paru M. Jaykrishna

Executive, Promoter, Chairperson

—

Gokul M. Jaykrishna

Executive, Promoter, MD

Arvind Ltd; The Anup Engineering

Arjun G. Jaykrishna

Executive, Promoter group, CEO

—

Mitesh N. Patel

Executive Director

—

Maulik Mehta

Non-executive (presumed independent)

Deputy MD, Deepak Nitrite; Independent Director, Transpek Industry

Shivani R. Lakhia

Non-executive (presumed independent)

Advocate (17+ years)

Samveg Lalbhai

Non-executive (presumed independent)

MD, Atul Ltd; boards of The Anup Engineering, Arvind Products, Bengal Tea & Fabrics

Anil Jain

Non-executive (presumed independent)

MD, Ascent Finechem; board of Hester Biosciences

Rupesh Shah

Independent Director (appointed 1 Jul 2026)

Five decades in ceramics and food processing

Sanjay Srivastava

Independent Director (additional director from 29 Jul 2026; five-year term proposed at AGM)

—

Board & Management Changes

DateChangeContext

May 2023

CFO Narendra Rathi resigns (personal reasons)

—

4 Apr 2026

Independent Director Sudhin Bhagwandas Choksey resigns

Letter dated 4 Apr 2026

9 Apr 2026

CFO Pratik Shah resigns with immediate effect (personal reasons)

Second CFO exit in three years

26 May 2026

Gokul Jaykrishna resigns as CEO (remains MD); Arjun Jaykrishna becomes CEO

Planned generational succession; resignation acceptance filed 17–18 Jun 2026

1 Jul 2026

Rupesh Shah appointed Independent Director

Replaces the vacancy

8 Jul 2026

Maulik P. Shah appointed CFO

Fills a three-month vacancy

29 Jul 2026

Sanjay Srivastava appointed Additional (Independent) Director; re-appointment of Paru and Gokul Jaykrishna as MD-level executives from 1 Aug 2026 approved by the board

AGM resolutions 5–8

Shareholding Trend

Holder category (%)Sep 2025Dec 2025Mar 2026Jun 2026

Promoter and promoter group

67.0067.0067.0067.00

Foreign portfolio investors

0.080.000.050.01

Other domestic institutions

0.030.300.310.32

Bodies corporate

4.213.833.713.02

Individuals (excluding promoters)

18.5018.8818.6919.19

Competitive Landscape

Competitors by Segment

SegmentCompetitorDescription / positioningSource of data

Phthalocyanine blue

Meghmani Organics (India)

Among the top three phthalocyanine pigment producers globally (Screener profile). FY26 pigment revenue about ₹461 crore at 3.3% EBITDA margin; pigment utilisation 40% (Q4 FY26 press release).

MOL press release; FilingReader

Phthalocyanine and broad organic pigments

Sudarshan Chemical Industries (India)

India's largest pigment company. Acquired the Heubach Group global pigments business (closed Mar 2025; Heubach had earlier acquired Clariant Pigments). FY26 consolidated revenue ₹9,787 crore.

Quartr; stockanalysis

Global inks and pigments (customer and competitor)

DIC Corporation / Sun Chemical (Japan / US)

World's largest ink-and-pigment group; also an Asahi customer and collaborator. Acquired BASF's pigments business in 2021.

General industry knowledge; CARE

Phthalocyanine and Azo (China)

Chinese producers (multiple, unnamed)

China accounts for more than half of global pigment production, particularly Azo (AR FY26). Aggressive price competition.

AR FY26

Phthalocyanine (India, unlisted / small-cap)

Other Gujarat phthalocyanine producers

India supplies more than 70% of global phthalocyanine demand. Capacity closures among weaker players occurred in the downturn (AR FY26).

AR FY26

Azo pigments (India)

Sudarshan; other organised and unorganised Indian Azo makers

AR FY26 says few organised Azo players operate in India

AR FY26

Inorganic and allied pigments

Ultramarine & Pigments (India)

Adjacent pigment player (ultramarine blue); limited direct overlap

General industry knowledge

Global organic pigments

Heubach (now within Sudarshan), Toyo Ink, Clariant (exited pigments)

Global consolidation context

Sudarshan disclosures

API — Pregabalin and CNS

—

Asahi (Atlas) claims Pregabalin market leadership; the basis is not specified

AR FY26

API — Chinese suppliers

Chinese API producers

Drove the 40–45% Pregabalin price collapse after 2022 (AR FY26)

AR FY26

Peer Comparison FY2026

MetricAsahi SongwonSudarshan Chemical (consolidated)Meghmani Organics (standalone)Meghmani — pigment segment only

Revenue

535.489,787.22,091.8

~461

Revenue growth YoY

-4.8%

+1.7% (as presented by company; reported basis up ~192% because Heubach was consolidated from Mar 2025)

+4%

Declined (Q2 FY26 -15% YoY)

EBITDA

56.53

579 (company adjusted)

228.7

~15 (3.3% margin)

EBITDA margin

10.4%

~5.9% adjusted (6.4% per aggregator)

~10.9%

3.3%

Net profit

17.78115.8125.3—

Pigment capacity utilisation

Blue 80–85%; Azo ~65% rising

——40%

Debt / equity

0.47—

0.47 (consolidated)

—

“—” = not publicly disclosed.

Company Snapshot

$61.8M

Revenue

1990

Founded

Ahmedabad, India

Headquarters

SWOT Analysis

Strengths

  • High utilisation through a down-cycle. Blue utilisation was 80–85% in FY26, versus 40% at Meghmani's pigment segment (company filings).
  • Backward integration. One tonne of crude is needed per tonne of finished blue, and Asahi makes its own crude. API intermediates are produced in-house at Chhatral (AR FY26).
  • Sticky blue-chip customers. DIC, Sun Chemical, Clariant and BASF are named by CARE. Supply agreements run up to 18 years and the longest relationship is 21 years (AR FY26).
  • Diversification achieved. Ink dependence has fallen from more than 90% to about 45% of revenue; customers have grown from 19 (2014) to 101 (AR FY26).
  • Earnings inflection. Q1 FY27 operating margin was 16.83%, up from 7.04%, and owners' net profit was ₹19.23 crore, up from ₹3.16 crore (Q1 FY27 filing).
  • Promoter commitment. Promoters hold 67.00% with zero pledge, and the promoter group bought shares in FY26 (shareholding filings).
  • Clean compliance record. The company reports no forced pollution shutdowns in a decade, about 80% water recycling, and WHO-GMP certification (AR FY26).

Weaknesses

  • Persistently low returns. ROE has been about 6% in FY24 to FY26 (AR FY26), below the cost of equity for an Indian small-cap. This reflects heavy, under-utilised capital.
  • Elevated leverage for the earnings base. Net debt is ₹140.78 crore, 2.5x FY26 EBITDA (derived).
  • Weak working-capital trends. Debtor turnover fell from 4.14x to 3.73x and inventory turnover from 6.51x to 5.03x in FY26 (AR FY26). Operating cash flow fell from ₹57.92 crore to ₹43.24 crore.
  • Sub-scale subsidiaries. Azo and API still posted pre-tax losses of ₹2.42 crore and ₹3.34 crore respectively in FY26 (AR FY26).
  • KMP turnover. Two CFO exits (2023 and 2026) and an independent director resignation in April 2026 (exchange filings).
  • Disclosure quality. The AR has internal inconsistencies (18 versus 19 export markets; Azo utilisation of 65% versus "mid-eighties"). R&D spend and segment history were not readily disclosed, and a KPI page contains garbled values.

Opportunities

  • API utilisation upside. Finished-API utilisation at Chhatral is about 30%, and management says the subsidiaries can reach ₹250–280 crore revenue without major capex (AR FY26).
  • CEP certification. Expected by end FY27, it opens access to regulated export markets and a higher-margin Pregabalin grade (AR FY26).
  • Azo exports and expansion. US and European approvals are reopening; an expansion of ₹10–15 crore would add about 50% capacity (AR FY26).
  • China+1 sourcing shift. China accounts for more than half of global pigment production, especially Azo (AR FY26).
  • Deleveraging. Each ₹10 crore of debt repaid saves roughly ₹1 crore of interest per year (derived from FY26 finance cost relative to debt).
  • Valuation re-rating. The trailing P/E is about 12x (derived) for a company guiding to an EBITDA potential of about ₹100 crore, versus ₹56.53 crore in FY26.

Threats

  • Chinese price aggression in pigments and APIs. Pregabalin prices fell 40–45% after the 2022 acquisition (AR FY26).
  • US tariffs and trade disruption, which hit Azo export approvals and third-country demand (AR FY26).
  • Raw-material spikes. In Q1 FY27 they caused Azo customers to defer purchases, and Azo revenue fell to ₹17.02 crore (MD commentary, Aug 2026).
  • Customer concentration. A few multinational ink makers anchor the blue business (AR FY26 risk section).
  • Currency. 69% export share; the hedge is partial, via imported raw materials (AR FY26).
  • Succession and key-person risk. A 30-year-old CEO was appointed in May 2026, and executive authority is concentrated in the founding family (AR FY26; scanx).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
5 Nov 2024Q2 FY25: consolidated revenue ₹141.61 crore (+48.6% YoY); standalone ₹99.46 crore (+71.7%) Company press releaseConfirms cyclical recovery
17–24 Jan 2025CARE upgrades to A; Positive / A1 (blue utilisation above 85%, Azo about 66%) CARE; BSE intimationFirst upgrade after three downgrades
31 Jan 2025Q3 FY25 results; de-bottlenecking output gains deferred to Q1 FY26 Company press releaseExecution timing slip
9 May 2025Q4 FY25 revenue ₹152.75 crore; FY25 revenue ₹562.36 crore (+31.94%); profit before exceptional items ₹16.86 crore Company press releasePeak-recovery year
Aug 2025Q1 FY26: revenue about ₹151 crore (+12% YoY); net profit about ₹2.6–3.2 crore (-39% to -41% YoY); pigment PBIT ₹7.8 crore, API loss ₹0.4 crore HDFC Sky; KotakMargin squeeze; stock fell 3.3% on the day
22 Aug 2025FY25 final dividend of ₹1.50 (15%) declared by the board; record date 5 Sep 2025 HDFC SkyTripled payout versus ₹0.50
12 Sep 202535th AGM approves FY25 dividend AR FY26 IEPF table—
11 Nov 2025Q2 FY26 results; EPS ₹1.91 Kotak; finanzenContinued weakness
Dec 2025Stock near ₹255, down about 39% over one year; market cap about ₹301 crore EquentisDe-rating on earnings weakness
22 Jan 2026Stock about ₹222.8, down 48.8% over six months Kotak NeoSentiment trough
29 Jan 2026Q3 FY26 results finanzen calendar—
Early 2026Stock touches 52-week low of about ₹179.64 (exact date not disclosed) Multiple aggregatorsCycle low
31 Mar 2026Company confirms it is not a "Large Corporate" under SEBI borrowing rules scanxBorrowings below threshold
4 Apr 2026Independent Director Sudhin Choksey resigns scanxBoard refresh needed
9 Apr 2026CFO Pratik Shah resigns with immediate effect boardstewardship.comKMP turnover
26 May 2026Gokul Jaykrishna steps down as CEO; Arjun Jaykrishna appointed CEO Exchange filing; AR FY26Generational succession
27–30 May 2026Q4 FY26: revenue ₹144.05 crore, EBITDA ₹23.02 crore (+30% YoY, 15.6% margin), PAT ₹10.82 crore (+57%); FY26 revenue ₹535.48 crore, PAT ₹17.78 crore Press release; Indian Chemical NewsStrongest quarter of FY26; Azo and API EBITDA-positive
30 May 2026Q4 FY26 investor presentation; postal ballot notice published Screener announcementsGovernance approvals
1–4 Jun 2026Q4 FY26 earnings call held; transcript filed Screener; arthneetiGuidance on blue EBITDA (₹50–55 crore) and Azo utilisation
17 Jun 2026Formal acceptance of CEO resignation filed boardstewardship.com—
1 Jul 2026Rupesh Shah appointed Independent Director scanxFills vacancy
8 Jul 2026Maulik P. Shah appointed CFO scanx; sahi.comStrengthens finance function
29 Jul 2026Q1 FY27: record revenue ₹188.91 crore (+26% YoY), net profit ₹19.2 crore (about 6x YoY), operating margin 16.83%. Board recommends FY26 dividend of ₹1.50, appoints Sanjay Srivastava as ID, and approves MD re-appointments. Exchange filing; marketsmojoEarnings inflection; stock ₹354.60 (+1.7%)
5–6 Aug 2026Q1 FY27 press release: segment split (Phthalo ₹138.14 crore, Azo ₹17.02 crore, API ₹34.54 crore); management flags Azo customer deferrals on raw-material spike and strong deleveraging Indian Chemical NewsMixed segment signals
Aug 2026Monitor
11 Aug 2026Stock falls 4.99% to ₹338.1 IIFLPost-results volatility
25 Aug 2026DSIJ feature frames Asahi as a diversified specialty-chemicals storyRising retail visibility
5 Sep 2026FY26 Annual Report ("Calibrated for growth") filed with NSE and BSE NSE filing₹1,000 crore ambition articulated
21 Sep 2026Stock about ₹364 on NSE Business StandardNear post-results levels
23 Sep 2026Record date for FY26 dividend AR FY26 Notice—
30 Sep 202636th AGM (virtual): dividend, two director re-elections by rotation, ID appointment, three executive re-appointments (special resolutions) AR FY26 NoticeGovernance continuity
~28 Oct 2026 (expected, unconfirmed)Q2 FY27 results finanzen calendarKey test of margin durability
1 Nov 2026FY2018-19 unclaimed dividends due for transfer to the Investor Education and Protection Fund (IEPF) AR FY26 NoticeAdministrative

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment: Phthalocyanine pigments (standalone proxy; FY26) rose from INR 2,765.8 Mn in FY2024 to INR 3,436 Mn in FY2026.
Asahi Songwon Colors Limited — Revenue by Segment
Series (INR Mn)FY2024FY2025FY2026
Phthalocyanine pigments (standalone proxy; FY26)2,765.83,902.23,436
Azo + API subsidiaries combined1,496.61,721.41,918.8
Consolidated revenue from operations4,262.45,623.65,354.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.